<< Back To Search

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT05789303
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and potentially lead to better management of the disease. Here are some key points about the study:
  • The treatment involves a unique combination of existing therapies, which may enhance their effectiveness when used together.
  • Participants will receive close monitoring and support throughout the study, ensuring their safety and well-being.
  • This study is designed to evaluate how well the combination therapy works compared to standard treatments.
  • Researchers are particularly interested in understanding the side effects and overall impact on patients' quality of life.
  • The study aims to gather data that could lead to new treatment guidelines and options for patients in the future.
Overall, this clinical study represents an important step in advancing treatment options and improving care for individuals facing this challenging condition.
Third Opinion AI Generated Synopsis

Trial Summary
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: